US Biosimilars See A Banner Year Despite Few Approvals
Multiple Products Compete On Key Molecules As Insulins Make Transition
Executive Summary
With several biologic molecules opened up to true multi-source competition over the course of 2020, the US biosimilars landscape now looks very different from the start of the year.
You may also be interested in...
US Savings Top $338bn In 2020
Savings achieved in the US through the use of generics and biosimilars hit a new high in 2020, reaching $338bn, according to new figures released by the AAM.
Industry Ready To Embrace Digitalization, Says IGBA
IGBA chair Sudarshan Jain has indicated that "companies are undergoing the change towards digital health," in the second part of an exclusive interview with Generics Bulletin in which Jain and IGBA secretary general Suzette Kox talk about the pandemic-driven shift towards digitalization and computerization.
AmerisourceBergen Sees Momentum Build In US Biosimilars
AmerisourceBergen’s senior director of biosimilars, Sean McGowan, believes that momentum is continuing to build for US biosimilars in 2021, especially with key developments involving insulins and interchangeability on the horizon.